secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2024-04-12T23:59:59+00:00
Accession:  0001193125-24-094756
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Sensei Bio enters consulting agreement with former CFO Erin Colgan for transition through April 30, 2024
--------------------------------------------------------------------------------

- Erin Colgan, former CFO, will provide transition services through April 30, 2024 under a consulting agreement.
- Consulting fee of $1,640 per business day.
- Exercise period for her existing vested stock options extended to October 7, 2024 or later per plan/award.
- Agreement expires automatically on April 30, 2024 unless terminated earlier.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312524094756/0001193125-24-094756-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312524094756/d796542d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-094756

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer